Compare MATW & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | KURA |
|---|---|---|
| Founded | 1850 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 841.6M |
| IPO Year | 1995 | 2015 |
| Metric | MATW | KURA |
|---|---|---|
| Price | $27.69 | $10.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 305.4K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 59.07 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,795,737,000.00 | $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | $39.19 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $21.95 | $5.45 |
| 52 Week High | $30.93 | $12.49 |
| Indicator | MATW | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 45.11 |
| Support Level | $25.33 | $8.53 |
| Resistance Level | $28.57 | $10.97 |
| Average True Range (ATR) | 0.78 | 0.52 |
| MACD | 0.08 | -0.17 |
| Stochastic Oscillator | 78.01 | 8.33 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.